We are building this new website to better deliver information. Find out more. We are building this new website to better deliver information. Find out more.
Let us know what you think.

Updates on 01/08/2017

Diphtheria

4.2.4 Vaccines and 4.2.12 Variations from product information

Amendment of text due to the discontinuation of a vaccine type, Pediacel. (Refer also Chapters, 4.2 Diphtheria4.3 Haemophilus influenzae type b4.14 Polio and 4.19 Tetanus).

4.2.7 Recommendations

Addition of text clarifying vaccination in laboratory workers.

View Diphtheria

Haemophilus influenzae type b (Hib)

4.3.4 Vaccines

Addition of text to clarify situations in which vaccine interchangeability will now need to be considered.

4.3.4 Vaccines, 4.3.7 Recommendations, 4.3.12 Variations from product information

Amendment of text due to the discontinuation of the Haemophilus b conjugate (PRP-OMP) vaccine (PedvaxHIB) (Refer also Chapter 2.1 Pre-vaccination).

Amendment of text due to the discontinuation of a vaccine type, Pediacel (Refer also Chapters, 4.2 Diphtheria, 4.12 Pertussis, 4.14 Polio and 4.19 Tetanus).

Hepatitis A

4.4.4 Vaccines

Amendment of text to align with new product information.

4.4.6 Dosage and administration

Correction of incorrect text, replacing ELISA units with antigen units and changing 12 months to 36 months.

Measles

4.9.4 Vaccines

Correction of text due to incorrect nomenclature (Refer also Chapters, 4.11 Mumps and 4.18 Rubella and 4.22 Varicella).

Updating of text for consistency with new product information. In particular, the source of animal derived gelatin was updated to specify porcine gelatin. (Refer also Chapters, 4.11 Mumps4.18 Rubella4.21 Typhoid4.22 Varicella and Appendices 3 & 4).

4.9.5 Transport, storage and handling

Amendment of text to align with new product information on storage of vaccine at various temperatures (Refer also Chapters, 4.11 Mumps and 4.18 Rubella).

4.9.10 Precautions, 4.9.11 Adverse events

Moving text on egg allergy from Precautions to Adverse Events to be consistent with other chapters (Refer also Chapters, 4.11 Mumps4.18 Rubella and 4.22 Varicella).

4.9.11 Adverse events

Addition of text on ovalbumin quantity in vaccine.

View Measles

Mumps

4.11.4 Vaccines

Correction of text due to incorrect nomenclature (Refer also Chapters, 4.9 Measles4.18 Rubella and 4.22 Varicella).

Updating of text for consistency with new product information. In particular, the source of animal derived gelatin was updated to specify porcine gelatin. (Refer also Chapters, 4.9 Measles4.18 Rubella4.21 Typhoid4.22 Varicella and Appendices 3 & 4).

4.11.5 Transport, storage and handling

Amendment of text to align with new product information on storage of vaccine at various temperatures (Refer also Chapters, 4.9 Measles and 4.18 Rubella).

4.11.11 Adverse events

Addition of text on egg allergy to Adverse Events to be consistent with other chapters. (Refer also Chapters, 4.9 Measles4.18 Rubella and 4.22 Varicella).

View Mumps

Pertussis (whooping cough)

4.12.4 Vaccines and 4.12.12 Variations from product information 

Amendment of text due to the discontinuation of a vaccine type, Pediacel. (Refer also Chapters, 4.2 Diphtheria4.3 Haemophilus influenzae type b4.14 Polio and 4.19 Tetanus).

Poliomyelitis

4.14.4 Vaccines and 4.14.12 Variations from product information

Amendment of text due to the discontinuation of a vaccine type, Pediacel. (Refer also to Chapters, 4.2 Diphtheria4.3 Haemophilus influenzae type b4.12 Pertussis and 4.19 Tetanus).

Rabies and other lyssaviruses

4.16.5 Rabies immunoglobulin 

Amendment of text relating to the use of immunoglobulin.

4.16.7 Dosage and administration 

Clarification of text relating to administration of the vaccine and immunoglobulin.

4.16.8 Recommendations

Removal of text referring to exposure in an animal that has been dead for 4 hours or more. Addition of text clarify the need for a risk assessment of exposure which should take into account both live and dead animals.

Addition of text providing further detail and clarification regarding situations in which exposure may have occurred and a person may be unaware or unable to communicate this.

Rotavirus

Amendment of text relating to the need for a third dose of vaccine.

View Rotavirus

Rubella

4.18.4 Vaccines

Amendment of text to align with new product information. In particular the source of animal derived gelatin was updated to specify porcine gelatin. (Refer also Chapters, 4.9 Measles4.11 Mumps4.21 Typhoid4.22 Varicella and Appendices 3 & 4).

Correction of text due to incorrect nomenclature (Refer also Chapter, 4.9 Measles4.11 Mumps and 4.22 Varicella).

4.18.5 Transport, storage and handling

Amendment of text to align with new product information on storage of vaccine at various temperatures (Refer also Chapters, 4.9 Measles and 4.11 Mumps).

4.18.11 Adverse events

Addition of text on egg allergy to Adverse Events to be consistent with other chapters (Refer also Chapters, 4.9 Measles4.11 Mumps4.18 Rubella and 4.22 Varicella).

View Rubella

Tetanus

Amendment of text due to the discontinuation of a vaccine type, Pediacel. (Refer also Chapters, 4.2 Diphtheria4.3 Haemophilus influenzae type b4.12 Pertussis and 4.14 Polio).

View Tetanus

Tuberculosis

4.20.10 Precautions

Addition of text to clarify when BCG vaccination should be deferred in people with skin conditions.

Typhoid fever

4.21.4 Vaccines

Amendment of text to align with new product information. In particular the source of animal derived gelatin was updated to specify bovine gelatin. (Refer also Chapters, 4.9 Measles4.11 Mumps4.18 Rubella4.22 Varicella and Appendices 3 & 4).

Varicella (chickenpox)

4.22.4 Vaccines

Amendment of text to align with new product information. In particular the source of animal derived gelatin was updated to specify porcine gelatin. (Refer also Chapters, 4.9 Measles4.11 Mumps4.18 Rubella4.21 Typhoid and Appendices 3 & 4).

Correction of text due to incorrect nomenclature (Refer also Chapters, 4.9 Measles4.11 Mumps and 4.18 Rubella).

4.22.11 Adverse events

Addition of text on egg allergy to Adverse Events to be consistent with other chapters. (Refer also Chapters, 4.9 Measles4.11 Mumps and 4.18 Rubella).

4.22.12 Public health management of varicella

Addition of text to section regarding giving neonates zoster immunoglobulin (ZIG) to clarify it is after primary varicella-zoster virus (VZV) infection of the mother.

Yellow fever

4.23.4 Vaccine

Amendment of text describing vaccine failure.

4.23.7 Recommendations

Editing of text relating to a booster dose to provide clarity.

Zoster (herpes zoster)

4.24.7 Recommendations

Addition of text reiterating importance of obtaining a medical history in patients prior to vaccination, to reiterate the contraindications regarding use of zoster vaccine in immunocompromised individuals and to provide further detail on what constitutes immunocompromise and how to manage inadvertent vaccination in these individuals.

4.24.9 Contraindications

Addition of text and table to reiterate the contraindications regarding use of zoster vaccine in immunocompromised individuals and to provide further detail on what constitutes immunocompromise and how to manage inadvertent vaccination in these individuals.

4.24.10 Precautions

Addition of text providing more specific detail of CD4 levels at which a person infected with HIV can receive zoster vaccine. (Refer also Chapter 3.3 Groups with special vaccination requirements).

4.24.11 Adverse events

Addition of text providing details of select serious outcomes where immunocompromised individuals have received zoster vaccine.